|

Balstilimab Clinical Trials

19 actively recruiting trials across 10 locations

Also known as: AGEN 2034, AGEN-2034, AGEN2034, AGEN2034, anti-PD-1 antibody, BAL +3 more

Pipeline

Phase 1: 3Phase 2: 11Phase 3: 2Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • Memorial Sloan Kettering Cancer Center3
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2
  • Weill Medical College of Cornell University1
  • University of Southern California1
  • University of Colorado, Denver1

Indications

  • Cancer19
  • Colorectal Cancer5
  • Metastatic Pancreatic Cancer2
  • Pancreatic Cancer2
  • Liver Disease1

Other5 trials

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Phase 2
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Phase 3
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Phase 3
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
Phase 2/3
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Phase 2

Basking Ridge, New Jersey3 trials

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Baltimore, Maryland2 trials

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 1/2
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Sidney Kimmel Comprehensive Cancer Center

Phase 1

Houston, Texas2 trials

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

MD Anderson Cancer Center

Phase 1/2
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

M D Anderson Cancer Center

Phase 2

Duarte, California1 trial

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

City of Hope Medical Center

Phase 2

Fullerton, California1 trial

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Saint Jude Medical Center / Providence Medical Foundation

Phase 1

Orange, California1 trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Children's Health Orange County (CHOC)

Phase 1

Aurora, Colorado1 trial

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

University of Colorado Hospital

Phase 2

Miami, Florida1 trial

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

University of Miami

Phase 2

Chicago, Illinois1 trial

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Northwestern University

Phase 2

New York, New York1 trial

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Weill Cornell Medicine/NewYork-Presbyterian Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.